Marché mondial de la néphropathie membraneuse – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché de la néphropathie membraneuse

Le marché mondial de la néphropathie membraneuse devrait croître à un rythme soutenu en raison du nombre croissant de troubles rénaux dans le monde et de la population âgée vulnérable. L'impact du COVID-19 sur le marché de la néphropathie membraneuse a commencé à se faire sentir. L'épidémie de cette maladie a conduit à des confinements dans le monde entier qui ont ralenti la croissance de nombreux marchés. Le marché de la néphropathie membraneuse n'est pas différent. Cependant, le marché devrait rattraper son retard et croître rapidement au cours des années de prévision.

Data Bridge Market Research analyse le taux de croissance du marché mondial de la néphropathie membraneuse au cours de la période de prévision 2022-2029. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe Data Bridge Market Research comprend également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché de la néphropathie membraneuse

Market Definition

Membranous nephropathy is also known as silent kidney problem and is considered as a form of glomerular disease. It is occurred when the glomeruli became damage and thickened that causes edema and heavy proteinuria. As a result, it leads to reduced kidney function and swelling. Membranous nephropathy can be caused by numerous factors such as autoimmune disease, use of certain medications such as nonsteroidal anti-inflammatory drugs, and exposure to certain infections such as hepatitis B, hepatitis C, and syphilis.

Global Membranous Nephropathy Market Dynamics

Drivers

• Rising Population and Hepatitis Cases

According to the reports of United Nations, in 2017 around over 962 million population were aged over 60 and above worldwide. United Nations has also projected that by 2050, the older population will likely reach 425 million. Moreover, according to WHO, around 71 million people are affected with hepatitis C globally. This increasing aging population and increasing hepatitis cases are likely to boost the growth of the membranous nephropathy market.

• Increased Clinical Studies and Government Initiatives

The global diabetic nephropathy market is estimated to be driven by the rising R&D investments in drug discovery and development and the rising prevalence of diabetes. For instance, Novartis AG has a potential drug LNP023 which is in phase 2 of clinical trials. This is expected to boost the market growth.

Opportunities

• Increasing Demand for Retail Pharmacies

Rise in the number of open angle glaucoma therapeutics being delivered through retail pharmacies and increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients choose retail pharmacies for purchasing drugs, as these are easily accessible.

• Rising Demand for Diagnostic Tests

The different diagnostic tests are expected to create opportunities for the market growth. Tests such as urine test (urinalysis), glomerular filtration rate test, blood test, an antinuclear antibody test, kidney biopsy, an anti-PLA2R antibody test, kidney ultrasound or Computed Tomography (CT), and others.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global membranous nephropathy market over a forecast period.

• High Cost

The huge expenditure of the treatment and diagnostic methods hamper the market growth. Treatment includes different types of therapy such as conservative therapy, non-Immunosuppressive therapy, immunosuppressive therapy that are impeding the growth of the market.

This global membranous nephropathy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global membranous nephropathy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Membranous Nephropathy Market Scope

The global membranous nephropathy market is segmented on the basis of treatment, drug class, type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Conservative Therapy
• Non-Immunosuppressive Therapy
• Immunosuppressive Therapy
• Others

Drug Class

• Alkylating Agents
• Cyclophosphamide
• Chlorambucil, Cyclic Peptides
• Tacrolimus
• MycophenolateMofetil
• Others

Type

• Primary
• Secondary

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Membranous Nephropathy Market Regional Analysis/Insights

The global membranous nephropathy market is analyzed and market size insights and trends are provided by treatment, drug class, type, distribution channel and end-user as referenced above.

The major countries covered in the global membranous nephropathy market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the growing cases of hepatitis infections, the presence of sophisticated medical facilities to maximize the treatment effectiveness for patient and increases focuses in the research and development activity.

L’Asie-Pacifique domine le marché en raison du taux de diagnostic élevé et de la présence d’acteurs clés dans cette région.

La section par pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.   

Analyse du paysage concurrentiel et des parts de marché mondiales de la néphropathie membraneuse

Le paysage concurrentiel du marché mondial de la néphropathie membraneuse fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché mondial de la néphropathie membraneuse.

Les principaux acteurs opérant sur le marché mondial de la néphropathie diabétique comprennent :

• Pfizer Inc (États-Unis)
• F. Hoffmann-La Roche SA (Suisse)
• Mylan NV (États-Unis)
• Fresenius Kabi AG (Allemagne)
• Hebei Changshan Biochemical Pharmaceutical Co. Ltd. (Chine)
• Hikma Pharmaceuticals PLC (Royaume-Uni)
• Novartis SA (Suisse)
• Teva Pharmaceutical Industries Ltd. (Israël)
• F. Hoffmann-La Roche SA (Suisse)
• Société Bristol Myers Squibb (États-Unis)
• FibroGen, Inc. (États-Unis)
• Mayne Pharma Group Limited (Australie)

SKU-54517